- Development of vizantin, a safe immunostimulant, based on the structure-activity relationship of trehalose-6,6′-dicorynomycolate
-
Vizantin, 6,6′-bis-O-(3-nonyldodecanoyl)-α,α′- trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6′- dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.
- Yamamoto, Hirofumi,Oda, Masataka,Nakano, Mayo,Watanabe, Naoyuki,Yabiku, Kenta,Shibutani, Masahiro,Inoue, Masahisa,Imagawa, Hiroshi,Nagahama, Masahiro,Himeno, Seiichiro,Setsu, Kojun,Sakurai, Jun,Nishizawa, Mugio
-
supporting information
p. 381 - 385
(2013/02/23)
-
- TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND
-
It is an object of the present invention to provide a trehalose compound having high immunopotentiating activity and low toxicity. The trehalose compound is represented by formula (1). (In the formula, X and X' each represents a phenyl, a naphtyl, R1-CHR1- (wherein R1 and R2 each represents a C7-C21 alkyl group or the like) or the like; and n and n' each independently represents an integer of 0-3). The compound exhibits a high activating effect on macrophages and neutrophils.
- -
-
Page/Page column 51; 52
(2011/08/08)
-
- TREHALOSE COMPOUND, PROCESS FOR PRODUCTION OF THE COMPOUND, AND IMMUNO-STIMULATIVE AGENT COMPRISING THE COMPOUND
-
An object of the present invention is to provide a novel trehalose compound that exhibits excellent immunostimulating activity and that can be supplied in a large quantity in an industrial scale, and a method for producing the trehalose compound, wherein
- -
-
Page/Page column 14-15
(2009/12/07)
-
- Use of branched chain fatty acids and derivatives thereof for inhibition of P-glycoprotein
-
The invention relates to the use of branched chain fatty acids (BFAs) and their derivatives for inhibition of the activity of P-glycoprotein (P-gp). In particular, the invention relates to the use of BFAs and their derivatives in the treatment of multi-drug resistant (MDR) tumors associated with increased activity of P-glycoprotein. The invention also relates to the use of the above-mentioned molecules for administration of biologically active molecules and diagnostic agents into cells associated with increased activity of P-gp, and for increasing accumulation of biologically active molecules and diagnostic agents in organs protected by biological barriers.
- -
-
-